Targeted therapy for viral hepatitis

Drugs of Today

Volumn 32, Issue 8, 1996, Pages 653-661

  Schuster, Martin J ^a   Wu, George Y ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; DRUG CARRIER; GLYCOPROTEIN; LIPOSOME; NUCLEOSIDE DERIVATIVE; RIBOZYME;

DRUG TARGETING; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; REVIEW; VIRUS REPLICATION;

EID: 0030471178     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Di Bisceglie, A M., Hoofnagle, J.H. Chronic viral hepatitis. In: Hepatology: A Textbook of Liver Disease, 3rd Ed. Zakim, D., Boyer, T.D. (Eds.). WB Saunders: Philadelphia 1996.
2. Perrillo, R.P. The management of chronic hepatitis B. Am J Med 1994, 96 (Suppl. 1A): 34-9S.
3. Maynard, J. E., Kane, M.A., Alter, M.J., Hadler, S.C. Control of hepatitis B by immunization: Global perspectives. In: Viral Hepatitis and Liver Disease. Zuckerman, A.J. (Ed.). Alan R. Liss: New York 1988.
4. Kiire, C.F. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa. Prog Liver Dis 1993, 11: 167-78.
5. Hoofnagle, J.H. Therapy of acute and chronic viral hepatitis. Adv Intern Med 1994, 39: 241-75.
6. Haria, M., Benfield, P. Interferon-α2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 1995, 50: 873-96.
7. Dhillon, A.P., Dusheiko, G.M. Pathology of hepatitis C virus infection. Histopathology 1995, 26: 297-309.
8. Zanetti, A.R., Tanzi, E., Romano, L., Mele, A. Epidemiology and prevention of hepatitis type C in Italy. Res Virol 1995, 146: 253-9.
9. Beasley, R.P , Hwang, L., Lin, C., Chien, C. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 1981, 2: 1129-33.
10. Bruix, J., Barrera, J.M., Calvet, X. et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989, 2: 1004-6.
11. Colombo, M., Kuo, G., Choo, Q.L. et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989, 2: 1006-8.
12. Perrillo, R.P., Schiff, E.R., Davis, G.L. et. al. A randomized, controlled trial of interferon-α2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. New Engl J Med 1990, 323: 295-301.
13. Davis, G.L. Interferon treatment of chronic hepatitis C. Am J Med 1994, 96 (Suppl. 1A): 41-6S.
14. Farci, P., Mandas, A., Coiana, A. et al. Treatment of chronic hepatitis D with interferon-α2a. New Engl J Med 1994, 330: 88-94.
15. Koeck, J., Theilmann, L., Galle, P., Schlicht, H.J. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology 1996, 23: 405-13.
16. Lerat, H., Berby, F., Trabaud, M.A. et al. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest 1996, 97: 845-51.
17. Meijer, D.K.F., Jansen, R.W., Molena, G. Drug targeting systems for antiviral agents: Options and limitations. Antivir Res 1992, 18: 215-58.
18. Meijer, D.K.F., Molema, G. Targeting of drugs to the liver. Semin Liver Dis 1995, 15: 202-56.
19. Wisse, E. An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. J Ultrastruct Res 1970, 31: 125-50.
20. Gregoriadis, G. The carrier potential of liposomes in biology and medicine (I). New Engl J Med 1976, 295: 704-10.
21. La Bonnardiére, C. Données préliminaires sur l'effet protecteur de l'inierféron couplé a des liposomes dans le modele souris-virus de l'hépatite murine. Ann Microbiol 1978, 129A: 397-402.
22. Ghosh, P., Bachhawat, B. Targeting of liposomes to hepatocytes. In: Liver Disease, Targeted Diagnosis and Therapy Using Specific Receptors and Ligands. Wu, G., Wu, C. (Eds.). Marcel Dekker: New York 1991, 87-104.
23. Spanjer, H.H., van Galen, M., Roerdink, F.H., Regts, J., Scherphof, G.L. Intrahepatic distribution of small unilamellar liposomes as a function of liposomal lipid composition. Biochim Biophys Acta 1986, 863: 224-30.
24. Hostetler, K.Y., Korba, B.E., Sridhar, C.N., Gardner, M.F. Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B-infected cells and enhanced hepatic uptake in mice. Antivir Res 1994, 24: 59-67.
25. Xie, H., Voronkov, M., Liotta, D.C. et al. Phosphatidyl-2́,3́-dideoxy-3́-thiacytidine: Synthesis and antiviral activity in hepatitis B- and HIV-1-infected cells. Antivir Res 1995, 28: 113-20.
26. Korba, B A., Xie, H., Wright, K.N. et al. Liver targeted antiviral nucleosides: Enhanced antiviral activity of phosphatidyl-dideoxyguanosine in woodchuck hepatitis virus infection in vivo. Hepatology 1996, 23: 958-63.
27. Ishii, Y., Aramaki, Y., Hara, T., Tsuchiya, S., Fuwa, T. Preparation of EGF labeled liposomes and their uptake by hepatocytes. Biochem Biophys Res Commun 1989, 160: 732-6.
28. Spanjer, H.H., Scherphof, G.L. Targeting of lactosylceramide-containing liposomes to hepatocytes in vivo. Biochim Biophys Acta 1983, 734: 40-7.
29. Soriano, P., Dijkstra, J., Legrand, A. et al. Targeted and nontargeted liposomes for in vivo transfer to rat liver cells of a plasmid containing the preproinsulin I gene. Proc Natl Acad Sci USA 1983, 80: 7128-31.
30. Ishihara, H., Hara, T., Aramaki, Y., Tsuchiya, S., Hosoi, K. Preparation of asialofetuin-labeled liposomes with encapsulated human interferon-γ and their uptake by isolated rat hepatocytes. Pharm Res 1990, 7: 542-6.
31. Ishihara, H., Hayashi, Y., Hara, T., Aramaki, Y., Tsuchiya, S., Koike, K. Specific uptake of asialofetuin-tacked liposomes encapsulating interferon-γ by human hepatoma cells and its inhibitory effect on hepatitis B virus replication. Biochem Biophys Res Commun 1991, 174: 839-45.
32. Yamauchi, H., Kikuchi, H., Sawada, M., Tomikawa, M., Hirota, S. Characterization and tissue distribution of liposomes containing lactose mono-fatty acid derivatives. J Microencapsul 1994, 11: 179-88.
33. Yamauchi, H., Kikuchi, H., Sawada, M., Tomikawa, M., Hirota, S. Selective uptake of liposomes containing lactose mono-fatty acid derivatives by hepatic parenchymal cells. J Microencapsul 1994, 11: 287-96.
34. Ghosh, P., Das, P.K., Bachhawat, B.K. Targeting of liposomes towards different cell types of rat liver through the involvement of liposomal surface glycosides. Arch Biochem Biophys 1982, 213: 266-70.
35. Schlepper-Schaefer, J., Huelsmann, D., Djovkar, A. et al. Endocytosis via galactose receptors in vivo. Ligand size directs uptake by hepatocytes and/or liver macrophages. Exp Cell Res 1986, 165: 494-506.
36. Szoka, F.C. The future of liposomal drug delivery. Biotech Appl Biochem 1990, 12: 496-500.
37. Machy, P., Leserman, L. Endocytosis of cell surface molecules and intracellular delivery of materials encapsulated in targeted liposomes. In: Targeting of Drugs II: Optimization Strategies. Gregoriadis, G., Allison, A.C., Poste, G. (Eds.). Plenum Press: New York 1990, 77-86.
38. Schwendener, R.A. The preparation of large volumes of sterile liposomes for clinical applications. In: Liposome Technology, 2nd Ed., Vol. I. Gregoriadis, G. (Ed.). CRC Press: Boca Raton 1993, 487-500.
39. Van Berkel, T.J.C., Kruijt, J.K., Kempen, H.J.M. Specific targeting of high density lipoproteins to liver hepatocytes by incorporation of a trisgalctoside-terminated cholesterol derivative. J Biol Chem 1985, 260: 12203-7.
40. Bijsterbosch, M.K., van Berkel, T.J.C. Uptake of lactosylated low-density lipoprotein by galactose-specific receptors in rat liver. Biochem J 1990, 270: 233-9.
41. Bijsterbosch, M.K., van Berkel, T.J.C. Lactosylated high density lipoprotein: A potential carrier for the site-specific delivery of drugs to parenchymal liver cells. Mol Pharmacol 1992, 41: 404-11.
42. Schouten, D., van der Kooij, M., Muller, J., Pieters, M.N., Bijsterbosch, M.K., van Berkel, T.J.C. Development of lipoprotein-like particles for drug targeting: Neo-high density lipoproteins. Mol Pharmacol 1993, 44: 486-92.
43. Hoeg, J.M., Demosky, S.J. Jr. Distinct hepatic receptors for low density iipoprotein and apolipoprotein E in humans. Science 1985, 227: 759-61.
44. Rensen, P.C.N., van Dijk, M.C.M., Havenaar, E.G., Bijsterbosch, M.K., Kruijt, J.K., van Berkel, T.J.C. Selective liver targeting of antivirals by recombinant chylomicrons - A new approach to hepatitis B. Nature Med 1995, 1: 221-5.
45. Ashwell, G., Morell, A.G. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol 1974, 41: 99-128.
46. Wu. G.Y., Wu., C.H., Stockert, R.J. Model of specific rescue of normal hepatocytes during methotrexate treatment of hepatic malignancy. Proc Natl Acad Sci USA 1983, 80: 3078-80.
47. Wu, G.Y., Wu, C.H., Rubin, M.I. Acetaminophen hepatoxicity and targeted rescue: A model of specific chemotherapy for hepatocellular carcinoma. Hepatology 1985, 5: 709-13.
48. Wu, G.Y., Keegan-Rogers, V., Franklin, S., Midford, S., Wu, C.H. Targeted antagonism of galactosamine toxicity in normal rat hepatocytes in vitro. J Biol Chem 1988, 263: 4719-23.
49. Wu, G. Y., Wu, C.H. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J Biol Chem 1987, 262: 4429-32.
50. Wu, G.Y., Wu, C.H. Receptor-mediated gene delivery and expression in vivo. J Biol Chem 1988, 263: 14621-4.
51. Wu, C.H., Wilson, J.M., Wu, G.Y. Targeting genes: Delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo. J Biol Chem 1989, 264: 16985-7.
52. Vera, D.R., Krohn, K.A., Stadalnik, R.C., Scheibe, P.O. Tc-99m-galactosylneoglycoalbumin: In vivo characterization of receptor-mediated binding to hepatocytes. Radiology 1984, 151: 191-6.
53. Galli, G., Maini, C.L., Orlando, P., Deleide, G., Valle, G. A radiopharmaceutical for the study of the liver: 99m-Tc-DTPA-asialoorosomucoid. J Nucl Med Allied Sci 1988, 32: 110-26.
54. Gallez, B., Lacour, V., Demeure, R. et al. Spin labelled arabinogalactan as MRI contrast agent. Magn Reson Imaging 1994, 12: 61-9.
55. Fiume, L., Mattioli, A., Balborli, P.G. et al. Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin. FEBS Lett 1979, 103: 47-51.
56. Fiume, L., Busi, C., Mattioli, A., Balboni, P.G., Barbanti-Brodano, G. Hepatocyte targeting of adenine-9-β-D-arabinofuranoside 5′-monophosphate (ara-AMP) coupled to lactosaminated albumin. FEBS Lett 1981, 129: 261-4.
57. Fiume, L., Bassi, B., Busi, C., Mattioli, A., Spinosa, G. Drug targeting in antiviral chemotherapy. A chemically stable conjugate of 9-β-D-arabinofuranosyl-adenine 5́-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells. Biochem Pharmacol 1986. 35: 967-72.
58. Fiume, L., Balboni, P.G., Bassi, B., Busi, C., Mattioli, A., Spinosa, G. 9-β-D-arabinofuranosyl-adenine 5́-monophosphate coupled to lactosaminated albumin is not metabolized in mouse bloodstream. Pharm Acta Helv 1986, 61: 342-4.
59. Fiume, L., Bassi, B., Bongini, A. Conjugates of 9-β-D-arabinofuranosyladenine 5′-monophosphate (ara-AMP) with lactosaminated albumin. Characterization of the drug-carrier bonds. Pharm Acta Helv 1988, 63: 137-9.
60. Fiume, L., Busi, C., Mattioli, A., Spinelli, C., Spinosa, G., Bongini, A. A conjugate of acyclovir monophosphate with lactosaminated albumin releases the phosphorylated drug in liver cells. Naturwissenschaften 1989, 76: 74-6.
61. Fiume, L., Busi, C., Preti, P., Spinosa, G. Conjugates of ara-AMP with lactosaminated albumin: A study on their immunogenicity in mouse and rat Cancer Drug Deliv 1987, 4: 145-50.
62. Janssen, R.W., Kruijt, J.K, van Berkel, T.J.C., Meijer, D.K.F. Coupling of the antiviral drug araAMP to lactosaminated albumin leads to specific uptake in rat and human hepatocytes. Hepatology 1993, 18: 146-52.
63. Fiume, L., Busi, C., Di Stefano, G., Mattioli, A. Coupling of antiviral nucleoside analogs to lactosaminated human albumin by using the imidazolides of their phosphoric esters. Anal Biochem 1993, 212: 407-11.
64. Ponzetto, A., Fiume, L., Forzani, B. et al. Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viraemia at doses lower than do the unconjugated drugs. Hepatology 1991, 14: 16-24.
65. Fiume, L., Betts, C.M., BUSI, C. et al. The pathogenesis of vacuoles produced in rat and mouse liver cells by a conjugate of adenine arabinoside monophosphate with lactosaminated albumin. J Hepatol 1992, 15: 314-22.
66. Fiume, L., Bonino, F., Mattioli, A. et al. Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin. Lancet 1988, 2: 13-5.
67. Torrani Cerenzia, M.R, Fiume, L., Busi, C. et al. Inhibition of hepatitis B virus replication by adenine arabinoside monophosphate coupled to lactosaminated albumin. Efficacy and minimal active dose (letter). J Hepatol 1994, 20: 307-9.
68. Torrani Cerenzia, M.R., Fiume, L., de Bernardi Venon, W. et al. Adenine arabinoside monophosphate coupled to lactosaminated albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects. Hepatology 1996, 23: 657-61.
69. Fiume, L., Di Stefano, G., Busi, C., Mattioli, A. A conjugate of lactosaminated poly-L-lysine with adenine arabinoside monophosphate, administered to mice by intramuscular route, accomplishes a selective delivery of the drug to the liver. Biochem Pharmacol 1994, 47: 643-50.
70. Di Stefano, G., Busi, C., Mattioli, A., Fiume, L. Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-L-lysine administered to mice by intramuscular route. Biochem Pharmacol 1995, 49: 1769-75.
71. Biessen, E.A., Beuting, D.M., Vietsch, H., Bijsterbosch, M.K., van Berkel, T.J.C. Specific targeting of the antiviral drug 5-iodo 2′-deoxyuridine to the parenchymal liver cell using lactosylated poly-L-lysine. J Hepatol 1994, 21: 806-15.
72. Fiume, L., Di Stefano, G., Busi, C. et al. Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine administered by intramuscular route. Hepatoiogy 1995, 22: 1072-7.
73. Groman, E.V., Enriquez, P.M., Jung, C., Josephson, L. Arabinogalactan for hepatic drug delivery. Bioconjug Chem 1994, 5: 547-56.
74. Enriquez, P.M., Jung, C., Josephson, L., Tennant, B.C. Conjugation of adenine arabinoside 5′-monophosphate to arabinogalactan synthesis, characterization, and antiviral activity. Bioconjug Chem 1995, 6: 195-202.
75. Goodarzi, G., Gross, S.C., Tewari, A., Watabe, K. Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen. J Gen Virol 1990, 71: 3021-5.
76. Blum, H.E., Galun, E., von Weizsaecker, F., Wands, J.R. Inhibition of hepatitis B virus by antisense oligodeoxynucleotides. Lancet 1991, 337: 1230.
77. Korba, B.E., Gerin, J.L. Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro. Antivir Res 1995, 28: 225-42.
78. Wakita, T., Wands, J.R. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. J Biol Chem 1994, 269: 14205-10.
79. Alt, M., Renz, R., Hofschneider, P.H., Paumgartner, G., Caselmann, W.H. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology 1995, 22: 707-17.
80. Offensperger, W.B., Offensperger, S., Walter, E. et al. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligonucleotides. EMBO J 1993, 12: 1257-62.
81. Von Weizsaecker, F., Blum, H.E., Wands, J.R. Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template. Biochem Biophys Res Commun 1992, 189: 743-8.
82. Beck, J., Nassal, M. Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. Nucleic Acids Res 1995, 23: 4954-62.
83. Ruiz, J., Wu, C.H., Ito, Y., Wu, G.Y. Design and preparation of a novel multimeric self-cleaving ribozyme. BioTechniques, in press.
84. Sakamoto, N., Wu, C.H., Wu, G.Y. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest, in press.
85. Chang, C., Weiskopf, M., Li, H.G. Conformational studies of nucleoprotein circular dichroism of deoxyribonucleic acid base pairs bound by polylysine. Biochemistry 1973, 12: 3028-32.
86. Chiou, H.C., Tangco, M.V., Levine, S.M. et al. Enhanced resistance to nuclease degradation of nucleic acids complexed to asialoglycoprotein-polylysine carriers. Nucleic Acids Res 1994, 22: 5439-46.
87. Wu, G.Y., Wu, C.H. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem 1992, 267: 12436-9.
88. Bartholomew, R.M., Carmichael, E.P., Findeis, M A., Wu, C.H., Wu, G.Y. Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks. J Viral Hepat 1995, 2: 273-8.
89. Nakazono, K., Ito, Y., Wu, C.H., Wu, G.Y. Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology 1996, 23: 1297-303.
90. Madon, J., Blum, H.E. Receptor-mediated delivery of hepatitis B virus DNA and antisense oligodeoxynucleotides to avian liver cells. Hepatology 1996, 24: 474-81.